Objective: To examine associations of perceived stress with cognitive symptoms among adults with systemic lupus erythematosus (SLE). Methods: Among 777 adult (18 years) SLE patients, the association of Perceived Stress Scale (PSS) scores with two self-reported cognitive symptoms was examined: forgetfulness (severe/moderate vs. mild/none; from the Systemic Lupus Activity Questionnaire) and difficulty concentrating (all/most vs. some/little/none of the time; from the Lupus Impact Tracker). The study used multivariable logistic regression to estimate the odds ratios (ORs) per minimal important difference (MID ¼ 0.5*SD) of PSS score and cognitive symptoms. Results: Forgetfulness and difficulty concentrating were reported by 41.7% and 29.5%, respectively. Women and those with less education and high disease activity had higher PSS scores and were more likely to report cognitive symptoms than their counterparts. With adjustment for age, race, sex, education, and disease activity, each MID increase in PSS score was associated with higher prevalence of forgetfulness (OR ¼ 1.43, 95% CI 1.29-1.47) and difficulty concentrating (OR ¼ 2.19, 95% CI 1.90-2.52). No substantial differences in this association by age, race, sex, or disease activity were noted. Conclusions: SLE patients, particularly those with high disease activity, report a high burden of cognitive symptoms, for which stress may be a modifiable risk factor. Lupus (2017) 26, 1064-1071.
Introduction
Signs and symptoms of cognitive dysfunction are common in systemic lupus erythematosus (SLE) patients, with about one-quarter to onehalf of patients experiencing some level of cognitive impairment. [1] [2] [3] Multiple biologic factors, such as immunologic mechanisms and neuropsychiatric involvement in SLE, to explain the so-called ''lupus brain fog'' have been explored. [4] [5] [6] However, psychosocial factors such as stress may also act as contributors to this impairment. High levels of perceived stress have been shown to be strongly associated with cognitive impairment in older adults generally 7, 8 and in other chronic, inflammatory diseases as diverse as HIV, 9 breast cancer, 10 and multiple sclerosis. 11 This association may also hold in SLE patients, in whom stress is commonly reported, with nearly half reporting major life stress in the past 6 months. 12 Stress represents one of many psychosocial factors that may interact with each other and with disease-related factors to produce symptoms of cognitive impairment in SLE, 13 but stress may also exert effects on cognitive function that are independent of the effects of diseasespecific SLE activity.
Thus, stress represents a potentially modifiable risk factor for poor cognitive function in SLE patients that would not be addressed by clinical approaches that primarily address the contribution of disease activity to cognitive dysfunction in SLE. 14, 15 However, few studies have explicitly examined the independent association of stress with cognitive dysfunction in SLE. While a recent Spanish study found that higher stress was associated with greater cognitive dysfunction in a small sample of SLE patients, 16 better understanding of this association in a larger, representative population of SLE patients-particularly, a population that includes African-American patients, who may experience stress and its effects on health differently 17 -will inform clinical care for the broader SLE population. Leveraging cross-sectional data from the ongoing US cohort Georgians Organized Against Lupus (GOAL), which enrolled large numbers of adult SLE patients who are African-American, we examined whether perceived stress was independently associated with reported cognitive symptoms, including forgetfulness and difficulty concentrating, among SLE patients and whether these associations were independent of SLE-specific disease activity. We also examined whether the association between stress and cognitive symptoms differed among subpopulations of interest.
Methods

Study design and population
We used a cross-sectional design to describe the association of perceived stress with cognitive symptoms in baseline data from the ongoing GOAL cohort study. Details of GOAL recruitment and data collection have been published previously. 18 Briefly, GOAL study participants were recruited primarily from the existing Georgia Lupus Registry, a population-based registry funded by the Centers for Disease Control and Prevention for the purpose of more accurately estimating the incidence and prevalence of SLE in metropolitan Atlanta. 19 The population-based cohort was further enriched with additional patients receiving SLE treatment at Emory University, at Grady Memorial Hospital (the only safety net hospital in Atlanta), or from community rheumatologists in metropolitan Atlanta, who were recruited by mail, by telephone, and in person. Eligible participants were adult patients (aged 18 years) with a documented diagnosis of SLE (4 revised American College of Rheumatology (ACR) criteria, 20 or three ACR criteria plus a diagnosis of SLE by the patient's treating board-certified rheumatologist).
Baseline (August 2011-July 2012) data were available for 800 patients. For analyses, patients were excluded if they were missing data on perceived stress (n ¼ 1) or cognitive symptoms (n ¼ 7). Because of small sample sizes, we were unable to stratify by race other than African-American or white; thus, patients were further excluded if their race was not African-American or white (n ¼ 15), leaving 777 SLE patients in the analytic sample. The Emory University Institutional Review Board, Grady Health System Research Oversight Committee, and Georgia Department of Public Health Institutional Review Board approved the GOAL study protocol. All GOAL participants provided informed consent.
Study variables
Perceived stress
Perceived stress was estimated using the 10-item Perceived Stress Scale (PSS) score, 21 which measures the degree to which the subject found life situations stressful during the prior month. PSS scores range from 0 to 40, with higher scores indicating greater perceived stress; mean scores in a probability-based US sample were 12.1 and 13.7 in males and females, respectively. 22 
Cognitive symptoms
Self-reported cognitive symptoms were taken from items included in instruments measuring disease activity and lupus impact at baseline. Forgetfulness Forgetfulness was assessed by the item ''In the past 3 months, how bad has your forgetfulness been?'' (with possible responses of ''no problem,'' ''mild,'' ''moderate,'' or ''severe'') from the Systemic Lupus Activity Questionnaire (SLAQ). 23 We dichotomized forgetfulness as severe/moderate vs. mild/none. Difficulty concentrating Difficulty concentrating was assessed by the item ''During the past 4 weeks, I experienced difficulty concentrating'' (with possible responses of ''none of the time,'' ''a little of the time,'' ''some of the time,'' ''most of the time,'' and ''all of the time'') from the Lupus Impact Tracker (LIT). 24 We dichotomized difficulty concentrating as all/most vs. some/little/none of the time.
Other variables
Sociodemographics, including age, sex, race, years of education completed, employment status, income, and marital status, were self-reported at baseline. Age was grouped into categories of 20-39, 40-59, and 60 years for stratified analyses. Current disease activity was assessed via SLAQ 23 (range 0-44, with higher scores indicating greater SLE-related disease activity). Strata for high vs. low disease activity were defined by the median SLAQ score, excluding the forgetfulness item. SLE duration was calculated as the number of years between age at SLE onset and age at survey. SLE-related organ damage was assessed via the self-administered Brief Index of Lupus Damage (BILD: range 0-30, with higher scores indicating greater levels of damage). 25, 26 
Statistical analysis
Sociodemographic and clinical patient characteristics were summarized overall, and PSS scores and cognitive symptoms were summarized overall and by select characteristics. Odds ratios (ORs) and 95% confidence intervals (CIs) for the associations between dichotomized cognitive symptoms and PSS score were estimated using multivariable logistic regression models. PSS score was transformed such that the resulting ORs represented relative change in odds per minimal important difference (MID), estimated as 0.5*SD, 27 since, to our knowledge, there is no published minimal clinically important difference for this non-clinical assessment, particularly in SLE. 28 Adjustment for the a priori confounders age, sex, race, education, and disease activity was performed. In sensitivity analyses, we examined the effects of additional adjustment for employment, income, marital status, and current steroid use. Stata v. 14 (StataCorp, College Station, TX) was used for all analyses, and the threshold for statistical significance was set at a ¼ 0.05.
Results
Patient characteristics
The mean age of patients at baseline was 46.4 years; 6.4% were male and 80.3% were African-American (Table 1) . Most had at least 12 years of education, but only 35.1% of patients were employed (with 67.1% of those who were not working being disabled) and nearly half earned <$20,000 annually ( Table 1 ). The mean duration of SLE at baseline was 14 years, and the median disease activity (SLAQ) score, excluding the forgetfulness symptom, was 15 ( Table 1) .
Perceived stress
The overall mean PSS score was 18, with the entire range of possible scores (0-40) represented in the cohort (Figure 1 ); 16.1% and 6.1% reported scores <10 and >30, respectively. PSS scores were, on average, higher in younger patients, patients with fewer years of education and with lower income, and patients who were not married ( Table 2 ). African-American and female participants reported higher stress scores than white and male participants, respectively, but no statistically Table 1 ).
Association of perceived stress with reported cognitive symptoms in a cohort of SLE patients Forgetfulness Overall, 42% of patients reported severe or moderate forgetfulness ( Table 2) ; 34% of these patients (14% of all patients) reported severe forgetfulness.
Female patients were nearly twice as likely as male patients to report severe or moderate forgetfulness (43% vs. 22%, P ¼ .003), but no differences by age or race were seen ( Table 2 ). Patients with the most years of education and highest income reported were less likely, whereas patients who were not working due to disability were more likely, to report forgetfulness, relative to other patients ( Table 2) . Forgetfulness was reported nearly three times more often with high vs. low disease activity (59% vs. 22%, P < .001; Table 2 ).
Overall, each MID increase in PSS score was associated with 60% higher reported forgetfulness (OR ¼ 1.60, 95% CI 1.46-1.74); adjustment for sociodemographics did not change the association (Figure 2 ). Further adjustment for disease activity resulted in only a slightly attenuated association (OR ¼ 1.43, 95% CI 1.29-1.57), despite high vs. low disease activity being associated with nearly three-fold greater prevalence of reported forgetfulness in the same model (OR ¼ 2.92, 95% CI 2.05-4.15). Additional adjustment for employment, income, marital status, and steroid use did not change the results substantially (data not shown). Finally, stratified analyses showed no statistically significant differences in association of PSS score with forgetfulness by age, sex, race, or disease activity (Table 3) , although the magnitude of the associations was stronger in males vs. females and in those with low vs. high disease activity.
Difficulty concentrating
Nearly one-third (30%) of patients reported difficulty concentrating all or most of the time ( Table 2) ; 35% of these patients (10% of all patients) reported difficulty concentrating all of the time. Female patients were 1.5 times more likely than male patients to report difficulty concentrating all or most of the time (30% vs. 20%, P < .001), but there were no differences by age or race ( Table 2) . As with forgetfulness, patients with the most years of education and highest income reported were less likely, and patients who were not working due to disability were more likely, to report difficulty concentrating, relative to other patients ( Table 2) . Those who were separated, divorced, or widowed were also more likely than married or never-married patients to report difficulty concentrating. Difficulty concentrating was reported nearly four times more often with high vs. low disease activity (45% vs. 12%, P < .001; Table 2 ). Overall, each MID increase in PSS score was associated with 2.3-fold higher prevalence of reported difficulty concentrating (OR ¼ 2.31, 95% CI 1.90-2.52); adjustment for sociodemographics did not change the association (Figure 2 ). Further adjustment for disease activity resulted in only a slightly attenuated association (OR ¼ 2.19, 95% CI 1.90-2.52), although high vs. low disease activity was associated with 2.7-fold greater prevalence of difficulty concentrating (OR ¼ 2.70, 95% CI 1.75-4.19). Additional adjustment for employment, income, marital status, and steroid use did not change the results substantially (data not shown). Finally, there were no differences in association of PSS score with difficulty concentrating by age, sex, race, or disease activity (Table 3 ).
Discussion
In this large, predominantly African-American US cohort of SLE patients, we found perceived stress levels to be high, with only about one-quarter of the population having scores below the comparable mean score in the general US population. 22 Furthermore, more than 40% of these patients reported moderate-to-severe problems with forgetfulness, and nearly 30% reported difficulty concentrating all or most of the time. Both stress scores and prevalence of these cognitive symptoms were positively associated with younger age, less education, lower income, and high disease activity. However, even with adjustment for these and other potentially confounding factors, higher stress scores remained strongly associated with higher prevalence of these cognitive symptoms.
These results suggest that, in addition to managing disease activity, an approach that also includes stress reduction may be necessary to manage cognitive symptoms in patients with SLE. For example, self-management programs may work to decrease stress among SLE patients. 29 Cognitive behavioral therapy has also been shown to decrease perceived stress in the SLE population. 30 In another randomized study of SLE patients, 31 a stress reduction program consisting of biofeedback-assisted cognitive behavioral therapy reduced pain perception and improved psychological and physical functioning. Although not currently available on a routine basis, these types of intervention could have multiple patient-centered benefits, in addition to the potential for decreasing perceived stress and improving cognitive symptoms.
One limitation of our study is the lack of measured cognitive performance. Peralta-Ramirez et al. 16 looked at the association between stress and measured cognitive domains (e.g., visual memory, fluency attention) in 21 Spanish patients and found a similar association between higher stress and poorer cognitive function. However, while the self-reported cognitive symptoms that were used as outcomes in this study may be only perceived and may not reflect underlying changes in cognitive processes, these symptoms remain associated with concomitant stress. Furthermore, SLE patients see the perceived cognitive impact of lupus (including impaired ability to think clearly, concentration problems, and memory problems) as a primary component of their overall health-related quality of life, which further affects other important aspects of their quality of life, particularly employment and social functioning. 32 We also have the advantage of being able to examine many more patients who are more representative of the diverse US population with SLE than in previous studies such as Peralta-Ramirez et al. 16 We were able to leverage this population to examine stress, cognitive symptoms, and their association across several subgroups of interest. Interestingly, older age (60 years) was not associated with higher prevalence of cognitive symptoms, as might be expected for indicators of cognitive dysfunction; in fact, the younger patients reported higher prevalence of these symptoms, as well as higher stress levels. While fewer reported cognitive symptoms among older patients may reflect changing expectations and better coping strategies with increasing age, it is still important to note that younger patients, who are more likely to be in school or to be employed or seeking employment, are reporting high prevalence of these potentially devastating cognitive symptoms. Male SLE patients were far less likely than female SLE patients to report cognitive symptoms, but our results suggest that the effect of stress on cognitive symptoms may be stronger in male vs. female SLE patients. However, the latter results did not reach statistical significance, which may be due to lack of power, given the small sample of male SLE patients. Notably, there were no differences by race in reported stress, cognitive symptoms, or their association, despite generally poorer SLE outcomes in African-American vs. white SLE patients. Other psychosocial factors, including fewer years of education, disabled employment status, lower income, and unmarried status, were all associated with higher reported stress and higher prevalence of cognitive symptoms. Disease activity was a stronger predictor of stress and cognitive symptoms than any individual psychosocial factor. However, disease activity and psychosocial factors combined still did not explain the strong association between higher stress and higher prevalence of reported cognitive symptoms. Even additional adjustment for other factors such as use of steroids, which have been shown to be associated with reduced cognitive function, 33 did not change the association.
There are several important limitations to this work not discussed above. In this cross-sectional study, causal inference is limited. Further, the cross-sectional nature of the study does not allow longitudinal examinations of cognitive symptoms or chronic stress (e.g., monthly stress inventories implemented by Peralta-Ramirez et al. 16 ) or the ability to distinguish effects of perceived stress on subsequent disease activity vs. effects of disease activity on subsequent perceived stress. However, regardless of the direction of this association, our results still suggest that a clinical approach that addresses both disease activity and stress reduction is likely to be more effective than an approach that primarily addresses disease activity. Another important limitation is that we did not have a comparison group; thus, we cannot know whether the prevalence of cognitive symptoms is higher than that in a similar or even matched population. Despite this, knowledge of the association between stress and cognitive symptoms among SLE patients still informs their clinical care. Finally, as in any observational study, there is the possibility of residual confounding. For example, unmeasured factors such as social support and coping strategies 12, 34, 35 might at least partially explain our results. Our study also had important strengths, including relatively large sample sizes allowing subgroup analyses, a population-based sample of SLE patients, and adequate representation of African-American SLE patients.
SLE patients of all ages may be highly susceptible to cognitive symptoms, which are often considered to be geriatric issues in the general population. Further, these cognitive symptoms are strongly associated with higher perceived stress, regardless of disease activity or other patient characteristics. Stress is a modifiable risk factor that could be incorporated into a more patient-centered approach to cognitive symptoms in SLE.
